SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Life Sciences soars on reporting stellar Q1 numbers

06 Aug 2014 Evaluate

Jubilant Life Sciences is currently trading at Rs. 199.90, up by 3.75 points or 1.91% from its previous closing of Rs. 196.15 on the BSE.

The scrip opened at Rs. 199.00 and has touched a high and low of Rs. 203.65 and Rs. 199.00 respectively. So far 124734 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 222.00 on 13-Jun-2014 and a 52 week low of Rs. 65.10 on 28-Aug-2013.

Last one week high and low of the scrip stood at Rs. 203.65 and Rs. 176.65 respectively. The current market cap of the company is Rs. 3201.55 crore.

The promoters holding in the company stood at 54.02% while Institutions and Non-Institutions held 27.58% and 18.39% respectively.

Jubilant Life Sciences reported a net profit of Rs 203.72 crore as compared to a net loss of Rs 105.88 crore for the quarter ended June 30, 2013. Its total income from operations has increased by 25.82% to Rs 1036.24 for the quarter under review from Rs 823.56 crore for the corresponding quarter of the previous year.

On the consolidated basis, the company has reported a net profit after taxes, minority interest and share of profit / (loss) of associates of Rs 4.28 crore for the quarter as compared to a net loss of Rs 52.62 crore for the same quarter in the previous year. Its total income from operations has increased by 8.38% at Rs 1473.13 crore for quarter under review as compared to Rs 1359.27 crore for the quarter ended June 30, 2013.

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×